Abstract:The present study was design to examine the effect of tautomerism upon the CoMFA results. Three selected data sets involving protropic tautomerism, which are 21 p-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors, 35 inhibitors of puromycin-sensitive aminopeptidase (PSA), and 67 anxiolytic agents, were used for this purpose. Atom-by-atom alignment technique was adopted to superimpose the molecules in the data sets onto a template. The structural alignments using different tautomeric forms had no significant difference except the atoms involved in tautomerism, which ensures, to a great extent, that the differences of the CoMFA results result primarily from the tautomerism. All-orientation and all-placement search (AOS-APS) based CoMFA models, in addition to the conventional ones, were derived for each system and proved to be capable of yielding much improved statistical results. In the cases of the data sets of HPPD inhibitors and PSA inhibitors, excellent AOS-APS CoMFA models (q2>0.8 with four components for the former and q2>0.7 with seven components for the latter) were obtained, and almost no significant difference in statistical quality was observed when using different tautomeric forms to derive the models. However, it was not the case when treating the data set of anxiolytic agents. The keto tautomer, which was the active form of the PBI type inhibitors, produced measurably better results (q2=0.54 with eight components) than that the enol one (q2=0.37 with five components), indicating the importance of selecting proper tautomer in the CoMFA studies. Furthermore, there existed some substantial differences of the electrostatic field contours between the two different tautomeric forms for all of the three systems considered, whereas the differences in the steric field contour maps were limited. This implies that the resulting new potent ligands may be quite different if one utilizes the CoMFA models of different tautomeric forms for guiding further structural refinements.

Comparative Molecular Field Analysis of Tyrosine Kinase Inhibitors

Recent Progress In Comparative Molecular Field Analysis

Comparative Molecular Field Analysis of γ-Hydroxy Butenolide Endothelin Antagonists

Comparative molecular field analysis of gamma-hydroxy butenolide endothelin antagonists

3D-QSAR Study for Inhibitors of Cyclin-Dependent Kinase 4

CoMFA of two classes of 4-hydroxyphenylpyruvate dioxygenase inhibitors

Molecular field analysis of two sets of non-peptide corticotropin-releasing hormone antagonists

3D-QSAR Studies on AChE Inhibitory Activities of 2-Phenoxy-indan-1-one Derivatives

Comparative Molecular Field Analysis Of Non-Peptidic Inhibitors Of Thrombin

3D-QSAR Studies on 4-Hydroxyphenylpyruvate Dioxygenase Inhibitors by Comparative Molecular Field Analysis (Comfa)

Studies of 3D-quantitative structure-activity relationships on a set of nitroaromatic compounds: CoMFA, advanced CoMFA and CoMSIA.

Pyrrolo[3,2-d]pyrimidine Derivatives As Type II Kinase Insert Domain Receptor (KDR) Inhibitors: CoMFA and CoMSIA Studies

Three-dimensional QSAR of HPPD inhibitors, PSA inhibitors, and anxiolytic agents: effect of tautomerism on the CoMFA models.

Studies on Three-Dimensional Qsar of Muscarinic Receptor Agonists

Common Pharmacophore Model and 3D-QSAR Analysis of Two Different Tyrphostin Families

Molecular description of pyrimidine-based inhibitors with activity against FAK combining 3D-QSAR analysis, molecular docking and molecular dynamics

Three-dimensional Quantitative Structure–activity Relationship Study on Paullones As CDK Inhibitors Using CoMSIA and CoMFA

Three-dimensional quantitative structure–activity relationship study for analogues of TQXs using CoMFA and CoMSIA

Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective β2-adrenergic receptor agonists

3D-QSAR study on the inhibitory activity of flavonoids on PIM-1 kinase

Rigorous Treatment of Multispecies Multimode Ligand-Receptor Interactions in 3D-QSAR: CoMFA Analysis of Thyroxine Analogs Binding to Transthyretin.